PE20190349A1 - Acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-ene-1-carboxilico y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adiccion y carcinoma hepatocelular - Google Patents
Acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-ene-1-carboxilico y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adiccion y carcinoma hepatocelularInfo
- Publication number
- PE20190349A1 PE20190349A1 PE2018000517A PE2018000517A PE20190349A1 PE 20190349 A1 PE20190349 A1 PE 20190349A1 PE 2018000517 A PE2018000517 A PE 2018000517A PE 2018000517 A PE2018000517 A PE 2018000517A PE 20190349 A1 PE20190349 A1 PE 20190349A1
- Authority
- PE
- Peru
- Prior art keywords
- cyclopent
- addiction
- epilepsy
- ene
- amino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 206010012335 Dependence Diseases 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title abstract 2
- 206010015037 epilepsy Diseases 0.000 title abstract 2
- 108010060511 4-Aminobutyrate Transaminase Proteins 0.000 title 1
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 title 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 title 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 102000003929 Transaminases Human genes 0.000 abstract 1
- 108090000340 Transaminases Proteins 0.000 abstract 1
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 abstract 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562239330P | 2015-10-09 | 2015-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190349A1 true PE20190349A1 (es) | 2019-03-07 |
Family
ID=58488679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018000517A PE20190349A1 (es) | 2015-10-09 | 2016-10-10 | Acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-ene-1-carboxilico y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adiccion y carcinoma hepatocelular |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9670141B2 (enExample) |
| EP (1) | EP3341355B1 (enExample) |
| JP (1) | JP6841821B2 (enExample) |
| KR (1) | KR102745965B1 (enExample) |
| CN (1) | CN108137484B (enExample) |
| AU (1) | AU2016334396B2 (enExample) |
| BR (1) | BR112018007026B1 (enExample) |
| CL (1) | CL2018000914A1 (enExample) |
| CO (1) | CO2018003828A2 (enExample) |
| DK (1) | DK3341355T3 (enExample) |
| ES (1) | ES2825349T3 (enExample) |
| HU (1) | HUE053429T2 (enExample) |
| IL (1) | IL258516A (enExample) |
| LT (1) | LT3341355T (enExample) |
| MX (1) | MX380592B (enExample) |
| PE (1) | PE20190349A1 (enExample) |
| PL (1) | PL3341355T3 (enExample) |
| PT (1) | PT3341355T (enExample) |
| WO (1) | WO2017062942A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6591532B2 (ja) | 2014-08-21 | 2019-10-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体 |
| CN108137484B (zh) * | 2015-10-09 | 2021-02-12 | 西北大学 | 作为用于治疗癫痫、成瘾和肝细胞癌的gaba氨基转移酶灭活剂的化合物 |
| HUE054985T2 (hu) | 2015-10-09 | 2021-11-29 | Boehringer Ingelheim Int | Spiro[3H-indol-3,2'-pirrolidin]-2(1H)-on vegyületek és számrazékok, mint MDM2-P53 inhibitorok |
| KR20240110989A (ko) * | 2017-02-08 | 2024-07-16 | 오비드 테라퓨틱스 인크. | 프라더-윌리 증후군 및 발작 장애들을 치료하는 방법들 |
| US10653652B2 (en) | 2018-02-08 | 2020-05-19 | Ovid Therapeutics Inc. | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction |
| US11771671B2 (en) | 2018-02-08 | 2023-10-03 | Ovid Therapeutics Inc. | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction |
| AU2019243586A1 (en) * | 2018-03-29 | 2020-10-15 | Ovid Therapeutics Inc. | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders |
| US10822301B2 (en) * | 2018-04-12 | 2020-11-03 | Northwestern University | 3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase |
| JP7475055B2 (ja) | 2018-05-25 | 2024-04-26 | ノースウェスタン ユニバーシティ | （ｓ）－３－アミノ－４－（ジフルオロメチレニル）シクロペンタ－１－エン－１－カルボン酸の合成法 |
| WO2019236938A1 (en) | 2018-06-07 | 2019-12-12 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders |
| US11203596B2 (en) | 2019-02-25 | 2021-12-21 | Northwestern University | Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity |
| US11078153B2 (en) | 2019-04-03 | 2021-08-03 | Northwestern University | 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase |
| CN110935495B (zh) * | 2019-11-29 | 2021-02-23 | 中国科学院电子学研究所 | Gaba和电生理微纳同步传感检测芯片及其制备方法 |
| US11993569B2 (en) | 2020-01-23 | 2024-05-28 | Northwestern University | 3-amino-4-halocyclopentene carboxylic acids as inactivators of aminotransferases |
| EP4301724A4 (en) * | 2021-03-03 | 2025-05-28 | Northwestern University | (S)-3-AMINO-4,4-DIHALOCYCLOPENT-1-CARBOXYLIC ACID AS SELECTIVE INACTIVATORS OF HUMAN ORNITHINE AMINOTRANSFERASE |
| US20250171397A1 (en) * | 2022-02-27 | 2025-05-29 | Northwestern University | (3s,4r)-3-amino-4-(difluoromethyl)cyclopent-1-ene-1-carboxylic acid and related compounds as selective inactivators of ornithine aminotransferase |
| KR20250034134A (ko) * | 2022-07-06 | 2025-03-10 | 오비드 테라퓨틱스 인크. | 암 치료에 있어서 (s)-3-아미노-4-(디플루오로메틸렌일)사이클로펜트-1-엔-1-카르복실산의 사용 |
| KR20250145687A (ko) * | 2023-02-17 | 2025-10-13 | 오비드 테라퓨틱스 인크. | 류마티스 관절염의 치료에 있어서 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복시산의 용도 |
| US20240285565A1 (en) | 2023-02-17 | 2024-08-29 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes |
| AU2024220869A1 (en) | 2023-02-17 | 2025-09-04 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis |
| IL322802A (en) | 2023-02-17 | 2025-10-01 | Ovid Therapeutics Inc | Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of gastrointestinal disorders and as an immunomodulatory agent |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794413B1 (en) * | 2002-07-19 | 2004-09-21 | Northwestern University | Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase |
| IL177609A (en) * | 2006-08-21 | 2015-11-30 | Yaron Ilan | Use of gobacoline or its analogue to produce a drug to treat liver carcinoma |
| CA2790820A1 (en) * | 2010-02-25 | 2011-09-01 | Northwestern University | Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor |
| AR087700A1 (es) * | 2011-08-30 | 2014-04-09 | Gilead Sciences Inc | Inhibidores de aldh-2 en el tratamiento de adicciones |
| CN108137484B (zh) * | 2015-10-09 | 2021-02-12 | 西北大学 | 作为用于治疗癫痫、成瘾和肝细胞癌的gaba氨基转移酶灭活剂的化合物 |
-
2016
- 2016-10-10 CN CN201680059069.9A patent/CN108137484B/zh active Active
- 2016-10-10 LT LTEP16854531.7T patent/LT3341355T/lt unknown
- 2016-10-10 PT PT168545317T patent/PT3341355T/pt unknown
- 2016-10-10 JP JP2018517734A patent/JP6841821B2/ja active Active
- 2016-10-10 HU HUE16854531A patent/HUE053429T2/hu unknown
- 2016-10-10 AU AU2016334396A patent/AU2016334396B2/en active Active
- 2016-10-10 BR BR112018007026-2A patent/BR112018007026B1/pt active IP Right Grant
- 2016-10-10 KR KR1020187013228A patent/KR102745965B1/ko active Active
- 2016-10-10 DK DK16854531.7T patent/DK3341355T3/da active
- 2016-10-10 MX MX2018004302A patent/MX380592B/es unknown
- 2016-10-10 WO PCT/US2016/056245 patent/WO2017062942A2/en not_active Ceased
- 2016-10-10 ES ES16854531T patent/ES2825349T3/es active Active
- 2016-10-10 US US15/289,480 patent/US9670141B2/en active Active
- 2016-10-10 PL PL16854531T patent/PL3341355T3/pl unknown
- 2016-10-10 PE PE2018000517A patent/PE20190349A1/es unknown
- 2016-10-10 EP EP16854531.7A patent/EP3341355B1/en active Active
-
2017
- 2017-05-04 US US15/586,730 patent/US9993449B2/en active Active
-
2018
- 2018-04-05 IL IL258516A patent/IL258516A/en active IP Right Grant
- 2018-04-09 CL CL2018000914A patent/CL2018000914A1/es unknown
- 2018-04-10 CO CONC2018/0003828A patent/CO2018003828A2/es unknown
- 2018-05-29 US US15/991,323 patent/US20180271816A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018004302A (es) | Acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxil ico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adiccion y carcinoma hepatocelular. | |
| CO2018000696A2 (es) | Derivados de 3-fenoximetil-[1,2,4]triazol-2-ona, 3-fenoximetil-[1,2,3]triazol-2-ona, 3-fenoximetil-piridazin-3(2h)-ona, 3-fenoximetil-indazol, 3-fenoximetil-tetrahidroindazol y 3-fenoximetil-pirazol | |
| IL284651B (en) | 3' utr sequences for stabilization of rna | |
| CL2016002573A1 (es) | Compuesto de ciclopropanamina y sus usos. | |
| CU24466B1 (es) | Compuestos derivados de d-fenilalanina-n-sustituido con biciclos aromáticos, método de preparación de las mismas y composiciones farmacéuticas que los contienen | |
| PH12016501632A1 (en) | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors | |
| CL2017002813A1 (es) | Proceso para preparar 4-amino-piridazinas | |
| EA201792503A1 (ru) | Соль (s)-kck s-кетамина, соль (r)-kck s-кетамина и способы получения s-кетамина | |
| DOP2017000149A (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| NZ747676A (en) | Process for the preparation of isoxazoline compounds | |
| CO2017001884A2 (es) | Polimorfos de selinexor | |
| PL3161154T3 (pl) | Zmodyfikowane polimerazy do ulepszonego włączania analogów nukleotydów | |
| MX2018012602A (es) | Nuevos compuestos como inhibidores de autotaxina y composiciones farmaceuticas que comprenden a los mismos. | |
| SV2017005405A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| MX2016001304A (es) | Polimorfo de inhibidores de syk. | |
| SV2017005434A (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| MX385914B (es) | Método para tratar un tumor cerebral | |
| PE20190979A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| MA41803A (fr) | Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques | |
| MX379854B (es) | Compuestos quimericos ramificados y lineales, polinucleotidos, usos y metodos para preparacion de los mismos. | |
| EA201691413A1 (ru) | Селективные антагонисты nr2b | |
| CO2017000950A2 (es) | Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos | |
| BR112017009289A2 (pt) | métodos de administrar composições de amantadina | |
| CR20170050A (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| TH1501002166A (th) | วิธีการผลิตกรด แอล-อะมิโน |